Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biotech Vaneck ETF (BBH)

Biotech Vaneck ETF (BBH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Van Eck Associates
  • Assets Under Management 347,644,300
  • Market Capitalization, $K 347,644
  • Shares Outstanding, K 2,647
  • 60-Month Beta 1.29
  • Price/Earnings ttm 19.24
  • Annual Dividend & Yield 0.55 (0.42%)
  • Most Recent Dividend 5.551 on 12/20/18
  • Management Fee 0.35%
  • Sectors:

    ETFs - Biotech

Price Performance

See More
Period Period Low Period High Performance
1-Month
118.65 +10.98%
on 10/14/19
132.19 -0.39%
on 11/12/19
+13.14 (+11.08%)
since 10/11/19
3-Month
113.89 +15.62%
on 10/02/19
132.19 -0.39%
on 11/12/19
+7.13 (+5.72%)
since 08/12/19
52-Week
103.25 +27.53%
on 12/24/18
132.80 -0.85%
on 03/04/19
+12.11 (+10.12%)
since 11/12/18

Most Recent Stories

More News
Risk-On Sentiments Are Back: ETFs to Play

The global market has been rallying hard since October. Investors can thus bet on these high-flying ETFs.

JJC : 41.10 (-0.87%)
ACWI : 76.98 (-0.01%)
USO : 11.87 (-0.17%)
EEM : 43.06 (-0.71%)
BBH : 131.77 (+0.63%)
QMOM : 31.38 (+0.97%)
KBWD : 21.69 (+0.09%)
XLB : 60.37 (+0.48%)
SPY : 308.82 (+0.15%)
Biotech ETFs in Focus on Impressive Q3 Earnings Results

Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.

BMY : 58.38 (+0.40%)
FBT : 134.45 (+0.73%)
IBB : 110.41 (+0.34%)
XBI : 84.00 (+0.37%)
BBH : 131.77 (+0.63%)
AMGN : 221.27 (+0.26%)
BIIB : 291.50 (-0.90%)
CELG : 109.99 (+0.38%)
ALXN : 109.41 (+0.37%)
GILD : 64.32 (-0.50%)
Value Biotech ETFs & Stocks to Buy Now

Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

ABBV : 86.43 (+0.90%)
BMY : 58.38 (+0.40%)
MRK : 84.13 (+1.02%)
RHHBY : 37.3900 (-0.44%)
LLY : 113.17 (+0.33%)
GSK : 44.51 (+0.56%)
XBI : 84.00 (+0.37%)
BBH : 131.77 (+0.63%)
AMGN : 221.27 (+0.26%)
BIIB : 291.50 (-0.90%)
CELG : 109.99 (+0.38%)
IDNA : 26.58 (+0.26%)
Top-Performing Biotech ETFs YTD

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.

RHHBY : 37.3900 (-0.44%)
BMY : 58.38 (+0.40%)
XBI : 84.00 (+0.37%)
BTEC : 33.86 (+0.73%)
BBH : 131.77 (+0.63%)
SBIO : 35.87 (+0.73%)
ILMN : 295.72 (+0.24%)
CELG : 109.99 (+0.38%)
GILD : 64.32 (-0.50%)
GLPG : 190.37 (+0.39%)
AMGN : 221.27 (+0.26%)
EC : 18.26 (-3.69%)
ARKG : 31.10 (+0.81%)
Amgen to Buy Celgene's Otezla: 5 ETF Drugs

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

NVS : 89.30 (+0.76%)
BMY : 58.38 (+0.40%)
BBH : 131.77 (+0.63%)
PJP : 60.16 (+0.13%)
IBB : 110.41 (+0.34%)
PBE : 51.62 (+0.39%)
CELG : 109.99 (+0.38%)
AMGN : 221.27 (+0.26%)
IEIH : 26.33 (+0.84%)
Biotech ETFs in Focus on Impressive Q2 Earnings Results

Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.

IBB : 110.41 (+0.34%)
FBT : 134.45 (+0.73%)
BBH : 131.77 (+0.63%)
XBI : 84.00 (+0.37%)
GILD : 64.32 (-0.50%)
ALXN : 109.41 (+0.37%)
AMGN : 221.27 (+0.26%)
BIIB : 291.50 (-0.90%)
AbbVie to Buy Allergan: Prescribed ETFs

AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.

BMY : 58.38 (+0.40%)
AGN : 181.96 (+0.21%)
ABBV : 86.43 (+0.90%)
BBH : 131.77 (+0.63%)
PPH : 60.16 (+1.19%)
XPH : 38.18 (-1.01%)
IHE : 144.14 (-0.08%)
PJP : 60.16 (+0.13%)
CELG : 109.99 (+0.38%)
Biotech ETFs in Focus on String of Q1 Earnings Beats

Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.

FBT : 134.45 (+0.73%)
BBH : 131.77 (+0.63%)
IBB : 110.41 (+0.34%)
BIB : 51.90 (+0.50%)
BIIB : 291.50 (-0.90%)
AMGN : 221.27 (+0.26%)
ALXN : 109.41 (+0.37%)
GILD : 64.32 (-0.50%)
Biotech ETFs in Focus on String of Q1 Earnings Beats

Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.

FBT : 134.45 (+0.73%)
BBH : 131.77 (+0.63%)
IBB : 110.41 (+0.34%)
BIB : 51.90 (+0.50%)
BIIB : 291.50 (-0.90%)
AMGN : 221.27 (+0.26%)
ALXN : 109.41 (+0.37%)
GILD : 64.32 (-0.50%)
Will Biotech ETFs Continue to Rally in Q1 Earnings?

Here we study the possible impact of some major Q1 earnings releases on certain biotech ETFs .

FBT : 134.45 (+0.73%)
BBH : 131.77 (+0.63%)
BIB : 51.90 (+0.50%)
IBB : 110.41 (+0.34%)
GILD : 64.32 (-0.50%)
ALXN : 109.41 (+0.37%)
AMGN : 221.27 (+0.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Good.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade BBH with:

Fund Summary

The VanEck Vectors Biotech ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index, which is intended to track the overall performance of companies involved in the development and production, marketing and sales of...

See More

Top 10 Holdings

Name % Holdings

See More

Key Turning Points

2nd Resistance Point 131.60
1st Resistance Point 131.28
Last Price 131.77
1st Support Level 130.65
2nd Support Level 130.34

See More

52-Week High 132.80
Last Price 131.77
Fibonacci 61.8% 121.51
Fibonacci 50% 118.03
Fibonacci 38.2% 114.54
52-Week Low 103.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar